|| Checking for direct PDF access through Ovid
A PHASE II STUDY of estradiol mustard was conducted by the Eastern Cooperative Oncology Group with four dosage schedules in 39 evaluable patients covering a wide range of tumor types. Sufficient hematologic toxicity occurred to indicate at least activity against normal hematopoietic stem cells. Only one response was noted (a partial response) in a patient with breast cancer who had responded previously to hormonal manipulation. A trial of the intermittent dosage, 80 mg/M2, might be considered in estrogen receptor-positive patients with breast cancer.